KCT0007688Recruiting未知
Establishment of Alzheimer's disease progression model after COVID-19 infection utilizing ACE2 and APOE gene polymorphisms, multimodal brain imaging, inflammatory, neurodegenerative biomarkers, and cognitive function changes in mild cognitive impairment patients: a pilot study
The Catholic University of Korea, Seoul St. Mary's Hospital0 sites65 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Recruiting
- Enrollment
- 65
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational Study
Eligibility Criteria
- Ages
- 55(Year) to 85(Year) (—)
- Sex
- All
Inclusion Criteria
- •? 55 years old or older and 85 years old or older
- •? Subjects who agreed to participate in this study
- •? Those who can participate in all the tests (comprehensive neuropsychological test, brain MRI, blood test) performed when participating in this study
- •? Satisfying mild cognitive impairment according to NIA-AA (National Institute on Aging-Alzheimer's Association) diagnostic criteria through structured interview with a psychiatrist.
- •? Clinical Dementia Rating (CDR): 0.5 points
Exclusion Criteria
- •? Those diagnosed with the following neurological diseases cannot participate in this study.
- •· Major neurodegenerative diseases such as Parkinson's disease and Huntington's disease
- •· Brain lesions accompanied by neurological disorders: brain tumor, progressive supranuclear palsy
- •Convulsive disorders that can cause Generalized Tonic-Clonic Seizures (GTCS)
- •Brain diseases that can cause secondary dementia, such as carbon monoxide poisoning or alcoholic dementia
- •? Those who have a history of abuse or dependence on alcohol or drugs within the past 2 years at the time of clinical research registration
- •? Those with medical conditions that can cause mental abnormalities - thyroid, liver disease, kidney disease, etc. The evaluation of the subject's disease is based on the medical judgment of the investigator
- •· Except for cases that may significantly interfere with neuropsychological evaluation due to the use of drugs such as antidepressants, antipsychotics, antianxiety drugs, or sedatives and sedatives according to the medical judgment of a specialist
- •? When other investigators judge that it is inappropriate to participate in clinical research.
Investigators
Similar Trials
Completed
Not Applicable
Alzheimer's disease, cognition and cerebrospinal fluid: Are they associated?Effect of anaesthesia and surgery on cognitionCerebrospinal fluid (CSF) predictors of cognitive change and Alzheimer's diseaeAnaesthesiology - AnaestheticsNeurological - Alzheimer's diseaseMental Health - Studies of normal psychology, cognitive function and behaviourAlzheimer's DiseaseACTRN12612000493842St. Vincent's Hospital54
Active, not recruiting
Phase 1
The GLP-1 receptor agonist liraglutide can slow down the progression of Alzheimer’s diseaseMedDRA version: 14.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 10029205 - Nervous system disordersAlzheimer's diseaseEUCTR2011-000794-31-DKDept. of Pharmacology
Completed
Not Applicable
Excavation of onset risk of Alzheimer's diseaseMild cognitive impairment (MCI) Healthy adult volunteersJPRN-UMIN000017442Department of Neurology Oita University Faculty of Medicine1,091
Active, not recruiting
Not Applicable
An observational study of factors influencing age of onset of Alzheimer’s disease and disease progressioNervous System DiseasesAlzheimer's diseaseISRCTN24454186lster University600
Recruiting
Not Applicable
PRedicting the EVolution of SubjectIvE Cognitive Decline to Alzheimer's Disease With Machine LearningCognitive DeclineMild Cognitive ImpairmentAlzheimer DiseaseNCT05569083Azienda Ospedaliero-Universitaria Careggi350